Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Transplant Infectious Disease
How do you dose maribavir in pediatric patients and on what is that based?
Related Questions
Do you manage antibacterials for enterococcal bacteremia differently in patients with severe immunosuppression?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Would you transition from IV to oral antibiotics in a solid organ transplant recipient with uncomplicated gram-negative bacteremia?
What is your preferred dosing of IV ganciclovir for CMV disease in immunocompromised patients?
Are there instances when you use letermovir without the addition of acyclovir when managing a kidney transplant recipient for CMV prophylaxis?
How would you manage persistent Norovirus diarrheal infections in a kidney transplant patient that are not responding to a decrease in the patient’s maintenance immunosuppressive regimen?
What are your top takeaways from ID Week 2024?
What factors influence your decision to initiate antifungal treatment in asymptomatic lung transplant recipients colonized with Aspergillus?
What is your preferred agent for fungal prophylaxis in a patient post lung transplant with abnormal LFTs?
Is the combination of a negative BAL PJP PCR and normal fungitell enough to rule out PJP pneumonia in an at-risk non-HIV patient?
